Ambulatory blood pressure patterns and the association with medication tolerability in heart failure with reduced/mildly reduced ejection fraction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20250218021

Enrollment

150

Registered

2025-02-18

Start date

2025-02-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with reduced ejection fraction ( HFrEF) Heart failure with mildly reduced ejection fraction ( HFmrEF) ABPM, HFrEF, HFmrEF

Interventions

Group with HFrEF and HFmrEF confirmed by echocardiogram or other assessments including cardiac MRI, nuclear scan, left ventriculogram with LVEF less than 50% within 1 year of enrollment.

Screening

Heart failure with reduced and mildly reduced EF

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2 Diagnosed of HFrEF or HFmrEF ( LVEF<50%) who optimized with foundation therapy 3 Consent to perform ABP monitoring

Exclusion criteria

Exclusion criteria: 1. Moderate or more degree of primary valvular heart disease 2. Complex congenital heart disease 3. Advanced stage of liver or kidney disease 4. Contraindication to foundation therapy ( RAASi, Beta blocker, MRA, SGLT2i)

Design outcomes

Primary

Measure	Time frame
Heart failure hospitalization/ Drug tolerability within 12 months of enrollment date frequency of heart failure hospitalization and maximal tolerability dose of foundation medications	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactSarawut Siwamogsatham

King Chulalongkorn Memorial Hospital

admin@chulacrc.org022516704

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026